Research graph
References from Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Effect of radiotherapy on painful bone metastases
10.1001/jamaoncol.2016.6770 · 2017 · External reference
Stereotactic ablative body radiotherapy for oligoprogressive estrogen receptor–positive breast cancer (TROG 20.03 AVATAR): a phase II prospective Multicenter Trial
10.1200/oa-25-00031 · 2025 · External reference
Stereotactic radiosurgery in the management of brain metastases: a case-based radiosurgery society practice guideline
2024 · External reference
Single- and multifraction stereotactic radiosurgery dose/volume tolerances of the brain
10.1016/j.ijrobp.2020.08.013 · 2021 · External reference
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
10.1016/s1470-2045(23)00534-x · 2024 · External reference
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
10.1016/j.annonc.2021.09.019 · 2021 · External reference
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
10.1016/s1470-2045(14)70178-0 · 2014 · External reference
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
10.1056/nejmoa1814017 · 2019 · External reference
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
10.1016/j.annonc.2021.04.011 · 2021 · External reference
Survival with trastuzumab emtansine in residual HER2-positive breast cancer
10.1056/nejmoa2406070 · 2025 · External reference
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
10.1038/s41591-025-03981-4 · 2025 · External reference
Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer
10.1056/nejmoa2508668 · 2026 · External reference
Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer
10.1056/nejmoa2407086 · 2024 · External reference
Trastuzumab deruxtecan in residual HER2-positive early breast cancer
10.1056/nejmoa2514661 · 2026 · External reference
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
10.1016/j.annonc.2025.10.019 · 2026 · External reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · 2021 · External reference
Sacituzumab govitecan in untreated, advanced triple-negative breast cancer
10.1056/nejmoa2511734 · 2025 · External reference
Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer
10.1056/nejmoa2508959 · 2026 · External reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · 2023 · External reference
SN-38 acts as a radiosensitizer for colorectal cancer by inhibiting the radiation-induced Up-regulation of HIF-1alpha
10.21873/anticanres.12598 · 2018 · External reference
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
10.1038/ncomms13019 · 2016 · External reference
Essential requirements for reporting radiation therapy in breast cancer clinical trials: an international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)
10.1016/j.radonc.2023.110060 · 2024 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Metaprop: a Stata command to perform meta-analysis of binomial data
10.1186/2049-3258-72-39 · 2014 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019 · External reference
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
2016 · External reference
Methodological quality of case series studies: an introduction to the JBI critical appraisal tool
2020 · External reference
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
10.1136/bmj.39489.470347.ad · 2008 · External reference
Unresolved reference
2013 · External reference
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
10.1007/s00280-014-2500-2 · 2014 · External reference
Unresolved reference
2024 · External reference
Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors
10.1002/cpt.2096 · 2021 · External reference
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
10.1056/nejmoa1914510 · 2020 · External reference
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
10.1002/cncr.30789 · 2017 · External reference
Correlation of high-sensitivity cardiac troponin i values and cardiac radiation doses in patients with left-sided breast cancer undergoing hypofractionated adjuvant radiotherapy with concurrent anti-HER2 therapy
10.3390/curroncol30100654 · 2023 · External reference
Clinical characteristics, treatment, and survival of thrombocytopenia induced by T-DM1 in early HER2-positive breast cancer
2025 · External reference
Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study
10.1186/s13058-025-02151-1 · 2025 · External reference
Concurrent use of trastuzumab deruxtecan and radiation therapy in HER2-positive and HER2-low metastatic breast cancer: a single-center experience and review of the literature
10.1097/coc.0000000000001135 · 2024 · External reference
Acute skin radiation toxicity seen with concurrent T-DM1: a single institutional report of 35 patients
10.1016/j.breast.2022.12.002 · 2023 · External reference
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort
10.1016/j.breast.2026.104691 · 2026 · External reference
Multicenter retrospective analysis of the safety and efficacy of sacituzumab govitecan combined with radiation therapy: the French attention study
10.1016/j.ijrobp.2025.07.1300 · 2025 · External reference
Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study
10.1007/s11060-024-04681-8 · 2024 · External reference
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases
10.1038/s41523-024-00711-w · 2024 · External reference
Local therapy for isolated central nervous system progression among patients receiving antibody-drug conjugate therapy
2025 · External reference
Breast CancerTrastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of combart prospective cohort study
10.1093/oncolo/oyaf229 · 2025 · External reference
Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer
2025 · External reference
The safety and efficacy of the combination of sacituzumab govitecan and palliative radiotherapy-a retrospective multi-center cohort study
10.3390/cancers16091649 · 2024 · External reference
Safety and tolerability of concurrent radiotherapy and sacituzumab govitecan in metastatic breast cancer
10.1097/coc.0000000000001195 · 2025 · External reference
Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery
10.1016/j.radonc.2024.110461 · 2024 · External reference
Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report
10.1007/s11060-025-05230-7 · 2025 · External reference
Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases
10.1038/s41523-025-00736-9 · 2025 · External reference
Safety of concurrent trastuzumab-emtansine and radiation therapy for breast cancer: single-centre experience from a morbidity and mortality review meetings procedure
10.1016/j.canrad.2024.07.019 · 2024 · External reference
Local therapy outcomes and toxicity from the ATEMPT Trial (TBCRC 033): a phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer
10.1016/j.ijrobp.2021.12.173 · 2022 · External reference
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer
10.1200/jco.2014.58.7782 · 2015 · External reference
Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2 + breast cancer
10.1007/s11060-022-04055-y · 2022 · External reference
Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4
10.1158/1078-0432.ccr-18-2851 · 2019 · External reference
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
10.1186/s12885-021-07971-w · 2021 · External reference
Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema
10.1093/neuonc/not329 · 2014 · External reference
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
10.1007/s10549-016-3828-6 · 2016 · External reference
adjuvant trastuzumab emtansine (T-DM1) and concurrent radiotherapy for residual invasive HER2-positive breast cancer: single-center preliminary results
10.1097/coc.0000000000000769 · 2020 · External reference
Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer
10.1007/s11060-016-2265-z · 2017 · External reference
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
10.1016/j.breast.2024.103756 · 2024 · External reference
Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors
10.1093/abt/tbaf004 · 2025 · External reference
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
10.1016/j.esmoop.2022.100554 · 2022 · External reference
Trastuzumab emtansine: mechanisms of action and drug resistance
10.1186/bcr3621 · 2014 · External reference
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
10.1002/mco2.671 · 2024 · External reference
